E. K. Ibragimov
Research Subjects
E. K. Ibragimov has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
D. A. Chekini
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
4 shared publications- Pervin A. Zeynalova
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University); Clinical Hospital "Lapino" of the "Mother and Child" Group of Companies
4 shared publications - Aleksandr Aleksandrovich Fedenko
P.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Center, Ministry of Health of Russia
3 shared publications - A. G. Zhukov
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
2 shared publications - Mikhail M. Davydov
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies; I. M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
2 shared publications - Nikita M. Kutakov
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
2 shared publications
Latest Publications
- Open Access
- 7 December 2023
- Published by Publishing House ABV Press in MD-Onco
- Vol. 3 (4) , 28-34
Optimal tactics of ovarian and metachronous breast cancer treatment in BRCA mutations carriers
Treatment of patients with multiple primary malignant neoplasms caused by genetic mutations requires correct priorities from the clinician in selection of the most effective therapeutic tactics. An important aspect in this case is the identification of the neoplasm determining patient’s survival. The main goal is to achieve maximal treatment effect for this tumor and use therapy methods for control of other synchronous and metachronous tumors.The article presents a clinical case of a patient with BRCA1 mutation-associated recurrent ovarian cancer and de novo breast cancer of negative subtype. Combination multidisciplinary and personalized approach to treatment which led to the maximally effective result is described. Personalized approach to prescription of antitumor drug therapy, timing of surgical intervention and subsequent targeted therapy allowed to realize maximal antitumor effect and increase the patient’s lifespan.
- 7 December 2023
- Published by Publishing House ABV Press in MD-Onco
- Vol. 3 (4) , 28-34
Open AccessOptimal tactics of ovarian and metachronous breast cancer treatment in BRCA mutations carriers
Treatment of patients with multiple primary malignant neoplasms caused by genetic mutations requires correct priorities from the clinician in selection of the most effective therapeutic tactics. An important aspect in this case is the identification of the neoplasm determining patient’s survival. The main goal is to achieve maximal treatment effect for this tumor and use therapy methods for control of other synchronous and metachronous tumors.The article presents a clinical case of a patient with BRCA1 mutation-associated recurrent ovarian cancer and de novo breast cancer of negative subtype. Combination multidisciplinary and personalized approach to treatment which led to the maximally effective result is described. Personalized approach to prescription of antitumor drug therapy, timing of surgical intervention and subsequent targeted therapy allowed to realize maximal antitumor effect and increase the patient’s lifespan.
- Open Access
- 11 September 2023
- Published by Publishing House ABV Press in Oncohematology
- Vol. 18 (3) , 35-43
An integrated treatment approach in patient with metastatic colorectal cancer and concomitant late cardiovascular complications of chemoradiotherapy for Hodgkin’s lymphoma. Clinical case
The high efficacy of the currently used combined chemoradiotherapy for Hodgkin’s lymphoma not only significantly increased overall survival, but also made it possible for most patients to achieve the same quality of life as in a healthy population. at the same time, the problem of identifying late treatment complications, in particular cardiovascular the high efficacy of the currently used combined chemoradiotherapy for Hodgkin’s lymphoma not only significantly increased overall survival, but also made it possible for most patients to achieve the same quality of life as in a healthy population. at the same time, the problem of identifying late treatment complications, in particular cardiovascular diseases, remains an urgent problem, the timely diagnosis of which is an important task. the development of a second malignant neoplasm and the appointment of drug antitumor therapy with cardiotoxic agents necessitate a multidisciplinary approach. In the presented clinical observation, such tactics of patient management made it possible not only to timely identify late cardiovascular complications of Hodgkin’s lymphoma chemoradiotherapy, but also to conduct treatment for the second malignant disease with cardiotoxic agents with a positive antitumor effect.
- 11 September 2023
- Published by Publishing House ABV Press in Oncohematology
- Vol. 18 (3) , 35-43
Open AccessAn integrated treatment approach in patient with metastatic colorectal cancer and concomitant late cardiovascular complications of chemoradiotherapy for Hodgkin’s lymphoma. Clinical case
The high efficacy of the currently used combined chemoradiotherapy for Hodgkin’s lymphoma not only significantly increased overall survival, but also made it possible for most patients to achieve the same quality of life as in a healthy population. at the same time, the problem of identifying late treatment complications, in particular cardiovascular the high efficacy of the currently used combined chemoradiotherapy for Hodgkin’s lymphoma not only significantly increased overall survival, but also made it possible for most patients to achieve the same quality of life as in a healthy population. at the same time, the problem of identifying late treatment complications, in particular cardiovascular diseases, remains an urgent problem, the timely diagnosis of which is an important task. the development of a second malignant neoplasm and the appointment of drug antitumor therapy with cardiotoxic agents necessitate a multidisciplinary approach. In the presented clinical observation, such tactics of patient management made it possible not only to timely identify late cardiovascular complications of Hodgkin’s lymphoma chemoradiotherapy, but also to conduct treatment for the second malignant disease with cardiotoxic agents with a positive antitumor effect.
- Open Access
- 14 December 2022
- Published by Publishing House ABV Press in MD-Onco
- Vol. 2 (4) , 56-62
A case of combination treatment of femoral osteosarcoma
Osteosarcomas are rare tumors with aggressive biology. It is important to refer such patients to a high-volume center, where an accurate diagnosis and optimal treatment are more likely to be performed. In contrast to Ewing's sarcoma, conventional osteosarcomas are believed to be generally resistant to radiation therapy, and the main treatment modalities are surgery and chemotherapy. In this clinical case, we demonstrate the efficacy of combined treatment of osteosarcoma of the femur.Preoperative chemotherapy allowed to evaluate tumor sensitivity to systemic treatment in vivo and optimize adjuvant treatment after R0 resection which allowed to achieve complete clinical response to treatment.
- 14 December 2022
- Published by Publishing House ABV Press in MD-Onco
- Vol. 2 (4) , 56-62
Open AccessA case of combination treatment of femoral osteosarcoma
Osteosarcomas are rare tumors with aggressive biology. It is important to refer such patients to a high-volume center, where an accurate diagnosis and optimal treatment are more likely to be performed. In contrast to Ewing's sarcoma, conventional osteosarcomas are believed to be generally resistant to radiation therapy, and the main treatment modalities are surgery and chemotherapy. In this clinical case, we demonstrate the efficacy of combined treatment of osteosarcoma of the femur.Preoperative chemotherapy allowed to evaluate tumor sensitivity to systemic treatment in vivo and optimize adjuvant treatment after R0 resection which allowed to achieve complete clinical response to treatment.
- Open Access
- 13 October 2022
- Published by Publishing House ABV Press in MD-Onco
- Vol. 2 (3) , 21-27
Neoadjuvant immunotherapy in treatment of oligometastatic locally advanced colon cancer. Clinical case
Immunotherapy has improved the results of treatment of patients with metastatic colorectal cancer. According to literature, the most cancericidal effect revealed in a microsatellite instability high (MSI-H) tumors. In our case, PD-1/PD-L1/PD-L2 inhibitors (nivolumab) treatment for locally advanced MSI-H colon carcinoma with liver metastasis in 44-year-old patient resulted in tumor regression, so that R0 surgical procedure became possible. Computed tomography scan and pathology report showed complete response, in primary and metastatic tumors. As a result, this allowed to improve the quality of patient’s life.
- 13 October 2022
- Published by Publishing House ABV Press in MD-Onco
- Vol. 2 (3) , 21-27
Open AccessNeoadjuvant immunotherapy in treatment of oligometastatic locally advanced colon cancer. Clinical case
Immunotherapy has improved the results of treatment of patients with metastatic colorectal cancer. According to literature, the most cancericidal effect revealed in a microsatellite instability high (MSI-H) tumors. In our case, PD-1/PD-L1/PD-L2 inhibitors (nivolumab) treatment for locally advanced MSI-H colon carcinoma with liver metastasis in 44-year-old patient resulted in tumor regression, so that R0 surgical procedure became possible. Computed tomography scan and pathology report showed complete response, in primary and metastatic tumors. As a result, this allowed to improve the quality of patient’s life.
- Open Access
- 13 October 2022
- Published by Publishing House ABV Press in MD-Onco
- Vol. 2 (3) , 36-42
CDK4/6 inhibitors in combination with hormone therapy in clinical practice. Clinical case
Currently, use of CDK4/6 inhibitors in combination with hormone therapy is approved for treatment of patients with advanced or metastatic breast cancer positive for estrogen and progesterone receptors and negative for human epidermal growth factor receptor 2 (HER2). In this clinical observation, analysis of the effectiveness of treatment of a patient with metastatic breast cancer of luminal A subtype is performed. The 1st line combination therapy was CDK4/6 inhibitors (ribociclib) and hormone therapy with aromatase inhibitors (letrozole) and analogues of gonadotropin-releasing hormone (goserelin) with concurrent bone-modifying denosumab therapy. Effectiveness of antitumor drug therapy administered for 7 months, and toxicity of the regimen were evaluated. Effectiveness of the selected combination treatment regimen was demonstrated and confirmed by clinical data, as well as results of laboratory and instrumental examinations. Adverse effects were controlled and managed with symptomatic therapy which allows to continue treatment using previously selected tactics.
- 13 October 2022
- Published by Publishing House ABV Press in MD-Onco
- Vol. 2 (3) , 36-42
Open AccessCDK4/6 inhibitors in combination with hormone therapy in clinical practice. Clinical case
Currently, use of CDK4/6 inhibitors in combination with hormone therapy is approved for treatment of patients with advanced or metastatic breast cancer positive for estrogen and progesterone receptors and negative for human epidermal growth factor receptor 2 (HER2). In this clinical observation, analysis of the effectiveness of treatment of a patient with metastatic breast cancer of luminal A subtype is performed. The 1st line combination therapy was CDK4/6 inhibitors (ribociclib) and hormone therapy with aromatase inhibitors (letrozole) and analogues of gonadotropin-releasing hormone (goserelin) with concurrent bone-modifying denosumab therapy. Effectiveness of antitumor drug therapy administered for 7 months, and toxicity of the regimen were evaluated. Effectiveness of the selected combination treatment regimen was demonstrated and confirmed by clinical data, as well as results of laboratory and instrumental examinations. Adverse effects were controlled and managed with symptomatic therapy which allows to continue treatment using previously selected tactics.
- Open Access
- 4 March 2022
- Published by Publishing House ABV Press in MD-Onco
- Vol. 2 (1) , 28-32-32
Effective application of integrative approach in treatment of neuroendocrine colon cancer. Clinical case
Neuroendocrine tumors are rare type of tumors of the gastrointestinal tract. Mostly the patient is diagnosed rather late, the tumors don’t have specific symptoms and there are no sensitive and specific methods of early diagnostics of the disease. Also, to date, the choice of antitumor treatment methods is limited. The article presents a clinical case of effective treatment of a neuroendocrine tumor of the colon with high level of microsatellite instability. After palliative partial colectomy, atypical resection of the liver, female patient with metastatic cancer of the descending colon has been receiving therapy with checkpoint inhibitors (PD-1) which led to long-term stabilization of the process.
- 4 March 2022
- Published by Publishing House ABV Press in MD-Onco
- Vol. 2 (1) , 28-32-32
Open AccessEffective application of integrative approach in treatment of neuroendocrine colon cancer. Clinical case
Neuroendocrine tumors are rare type of tumors of the gastrointestinal tract. Mostly the patient is diagnosed rather late, the tumors don’t have specific symptoms and there are no sensitive and specific methods of early diagnostics of the disease. Also, to date, the choice of antitumor treatment methods is limited. The article presents a clinical case of effective treatment of a neuroendocrine tumor of the colon with high level of microsatellite instability. After palliative partial colectomy, atypical resection of the liver, female patient with metastatic cancer of the descending colon has been receiving therapy with checkpoint inhibitors (PD-1) which led to long-term stabilization of the process.